The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miura, K.
Right arrow Articles by MacGlashan, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miura, K.
Right arrow Articles by MacGlashan, D. W., Jr.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 1999, 162: 4198-4206.
Copyright © 1999 by The American Association of Immunologists

Extracellular Signal-Regulated Kinases Regulate Leukotriene C4 Generation, But Not Histamine Release or IL-4 Production from Human Basophils1

Katsushi Miura, John T. Schroeder, Walter C. Hubbard and Donald W. MacGlashan, Jr.2

Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Human basophils secrete histamine and leukotriene C4 (LTC4) in response to various stimuli, such as Ag and the bacterial product, FMLP. IgE-mediated stimulation also results in IL-4 secretion. However, the mechanisms of these three classes of secretion are unknown in human basophils. The activation of extracellular signal-regulated kinases (ERKs; ERK-1 and ERK-2) during IgE- and FMLP-mediated stimulation of human basophils was examined. Following FMLP stimulation, histamine release preceded phosphorylation of ERKs, whereas phosphorylation of cytosolic phospholipase A2 (cPLA2), and arachidonic acid (AA) and LTC4 release followed phosphorylation of ERKs. The phosphorylation of ERKs was transient, decreasing to baseline levels after 15 min. PD98059 (MEK inhibitor) inhibited the phosphorylation of ERKs and cPLA2 without inhibition of several other tyrosine phosphorylation events, including phosphorylation of p38 MAPK. PD98059 also inhibited LTC4 generation (IC50 = ~2 µM), but not histamine release. Stimulation with anti-IgE Ab resulted in the phosphorylation of ERKs, which was kinetically similar to both histamine and LTC4 release and decreased toward resting levels by 30 min. Similar to FMLP, PD98059 inhibited anti-IgE-mediated LTC4 release (IC50, ~2 µM), with only a modest effect on histamine release and IL-4 production at higher concentrations. Taken together, these results suggest that ERKs might selectively regulate the pathway leading to LTC4 generation by phosphorylating cPLA2, but not histamine release or IL-4 production, in human basophils.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Stimulation of human basophils by cross-linking Fc{epsilon}RI (high affinity IgE receptor) or the bacteria product FMLP elicits the release of preformed mediator (histamine) and de novo synthesized lipid mediator (LTC4)3 (1, 2). Fc{epsilon}RI-mediated stimulation also results in the production of IL-4; however, FMLP is a poor stimulus for IL-4 (3, 4). In allergic diseases (bronchial asthma, allergic rhinitis, and atopic dermatitis), basophils infiltrate and secrete histamine and LTC4 at specific reaction sites in the skin, nose, and lung (5, 6, 7). Histamine and LTC4 derived from basophils are thought to be the main factors of the late phase allergic response. IL-4 induces cross-switching of IgG to IgE in B lymphocytes and increases the expression of VCAM-1 on endothelial cells, which promotes the infiltration of additional eosinophils and basophils into inflamed tissues, suggesting that basophils also contribute to chronic allergic inflammation.

The signal transduction events leading to these mediator secretions are not well understood in human basophils. Histamine is a preformed mediator in granules and is released upon stimulation of various stimuli. LTC4 is a de novo synthesized lipid mediator that is converted from arachidonic acid (AA) by 5-lipoxygenase and LTC4 synthase (8). The production of LTC4 might be controlled by the availability of free AA (9). The cytokine, IL-4, is a newly generated protein that may involve increased transcription. These three distinct classes of mediators may be differentially regulated and secreted from human basophils. We and others previously reported several similar and dissimilar characteristics for secretion of these mediators from human basophils (1, 2, 3, 10).

The p42/p44 mitogen-activated protein kinases (MAPKs), referred to as extracellular signal-regulated kinases (ERK-2 and -1), transduce signals elicited via several receptors that either have intrinsic tyrosine kinase activity or are associated with nonreceptor tyrosine kinases (11). ERK-1 (p44MAPK) and ERK-2 (p42MAPK) are approximately 90% homologous, suggesting functional redundancy (12). ERKs are activated by MAP kinase kinases (MEKs), which phosphorylate the TEY domain on tyrosine and threonine residues (13). The phosphorylation of tyrosine and threonine residues in ERKs is required for their full activation (12). Several transcription factors have been identified in eukaryotic cells as targets of ERKs (14). For example, the induction of c-Fos is thought to be mediated by ERKs via phosphorylation of the transcription factor TCF/Elk 1 (ternary complex factor) (15). ERKs also activate cytoplasmic enzymes such as cytosolic phospholipase A2 (cPLA2), which is important in the release of AA (16).

The role of ERKs in the signaling cascade of events leading to the release of inflammatory mediators and cytokines from human basophils has not been reported. However, there is evidence that these kinases are involved in the signal transduction pathways occurring with Fc{epsilon}RI-mediated activation of rodent mast cells. In rat basophilic leukemia cells (RBL-2H3 cells), the aggregation of Fc{epsilon}RI initiates a cascade of events that includes the activation of src-related tyrosine kinases, Lyn and Syk (17, 18, 19), and the tyrosine phosphorylation of various proteins (20, 21). The activation of ERKs is apparent from the tyrosine phosphorylation and shift in electrophoretic migration of ERK-2 (p42MAPK) and, to a lesser extent, of ERK-1(p44MAPK) as well as from an increase in ERK activity (22). There have been several attempts to associate the role of ERKs in degranulation, the release of AA, and the production of TNF-{alpha} following Fc{epsilon}RI-mediated stimulation (22, 23, 24). More recently, Zhang et al. provided evidence that ERK-2 (p42MAPK) activation contributed to the release of AA and the production of TNF-{alpha}, but not to the release of hexosaminidase (a marker of degranulation) (24). The causal association of ERK activation with the release of AA and TNF-{alpha} was based on studies with the selective MEK inhibitor, PD98059 (24). Thus, it is likely that ERKs regulate the pathways leading to the release of AA (by activating cPLA2) and the production of TNF-{alpha}, but not degranulation, in IgE-dependent stimulation in RBL-2H3 cells. Their role in regulating LTC4 formation in RBL-2H3 cells has not been fully elucidated because of the inability of these cells to generate LTC4. However, the opposite results for TNF-{alpha} production were obtained in MC/9 murine mast cells (25). Inhibition of ERKs with PD98059 had little effect on Fc{epsilon}RI-stimulated TNF-{alpha} production in these cells. In contrast, the MEKK1-regulated JNK pathway activated by Fc{epsilon}RI was shown to be mediated by this cytokine production (25). These two conflicting results (RBL-2H3 cell data vs MC/9 murine mast cell clone data) suggest that the role of ERKs may be different in distinct cells (even with the same stimulation; Fc{epsilon}RI-mediated stimulation). Therefore, the studies using normal human cells to examine the role of ERKs in cell functions should be important.

We have recently showed that the activation of cPLA2 is associated with free AA generation and LTC4 release in human basophils (26). Although there is conflicting evidence for the enzymatic source of AA in IgE-mediated stimulation of human basophils (26, 27), our most recent evidence favors the view that activation of cPLA2 is more closely associated with the AA generated and used for LTC4 formation. However, the causal relationship between cPLA2 activation and AA/LTC4 generation has yet to be determined, since there is no selective inhibitor for cPLA2. ERKs are known to phosphorylate and activate cPLA2 and may regulate transcriptional factors for cytokine production, but these have not been examined in human basophils.

Recently, it has been shown that another MAPK family member, p38 MAPK (the mammalian homologue HOG1 from yeast), rather than ERKs may have a role in the regulation of release of AA by activating cPLA2 in a particular cell type, platelets (28, 29, 30, 31). Moreover, p38 MAPK is known to regulate a transcriptional factor (ATF-2), thereby mediating new protein synthesis, including cytokines (32, 33, 34).

The current studies have examined the characteristics of ERK1/2 and p38 MAPK activation in human basophils, and their relationship to the secretion of the three major classes of mediators (histamine, LTC4, and IL-4). We show that ERK activation is responsible for the release of LTC4 from human basophils, but appears to have little if any role in histamine and IL-4 secretion.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials

The following were purchased: PIPES, BSA, EGTA, EDTA, D-glucose, NaF, Na4P2O7, Na3VO4, 2-ME, Nonidet P-40, and Tris-HCl (Sigma, St. Louis, MO); crystallized human serum albumin (HSA; Miles Laboratories, Elkhart, IN); FCS and RPMI 1640 containing 25 mM HEPES and L-glutamine (BioWhittaker, Walkersville, MD); Percoll (Pharmacia, Piscataway, NJ); Tris and Tween-20 (Bio-Rad, Hercules, CA); leupeptin, DTT, and PMSF (Boehringer Mannheim, Indianapolis, IN); rabbit anti-ERK-1 Ab, rabbit anti-ERK-2 Ab, and rabbit anti-p38 MAPK Ab (Santa Cruz Biotechnology, Santa Cruz, CA); anti-phosphotyrosine mAb (4G10; Upstate Biotechnology, Lake Placid, NY); rabbit anti-phospho-ERK (MAPK) Ab, recombinant ERK-2 (p42MAPK) protein, rabbit anti-phospho-p38 MAPK Ab, and biotinylated m.w. markers (New England Biolabs, Beverly, MA); peroxidase-linked donkey anti-rabbit Ig Ab and peroxidase-linked sheep anti-mouse Ig Ab (Amersham, Arlington Heights, IL); and PD98059 (Calbiochem, La Jolla, CA). Rabbit anti-cPLA2 Ab was provided by Dr. Lisa Marshall (SmithKline Beecham, King of Prussia, PA). Goat anti-human IgE was prepared as previously described (1).

A stock solution of PD98059 was prepared in DMSO. Controls were incubated with an equal concentration of DMSO.

Buffers and media

PIPES-albumin-glucose (PAG) buffer consisted of 25 mM PIPES, 110 mM NaCl, 5 mM KCl, 0.1% glucose, and 0.003% HSA. PAGCM was PAG supplemented with 1 mM CaCl2 and 1 mM MgCl2. PAG-EDTA consisted of PAG supplemented with 4 mM EDTA. Countercurrent elutriation was conducted in PAG containing 0.25% BSA in place of 0.003% HSA.

Basophil purification

Basophils were purified from residual cells of normal donors undergoing leukapheresis using Percoll density gradient and countercurrent flow elutriation as previously described (3). In all experiments involving the use of Western blot analysis of phosphorylated proteins, basophil purities were >80% as determined by Alcian blue staining (35). Basophil preparations of >73% purity were also used in studies involving the use of MEK inhibitor, PD98059.

The expression of ERKs and p38 MAPK in human basophils was initially performed on basophils further purified by positive selection as previously described (26, 36). This entire procedure was carefully performed at a temperature below 4°C and in the presence of PAG-EGTA (50 µM) to minimize concerns that the positive selection technique might induce changes in ERKs status. Cells were incubated for 10 min with 1 µg/ml mouse anti-human IgE (TES-19, provided by Dr. Frances Davis, Tanox) in the presence of 4 mg/ml normal human IgG to block Fc{gamma}R. After a subsequent 20-min incubation with rat anti-mouse IgG2a+b paramagnetic beads (8 µl/107 cells), the cells were passed through a MACS minicolumn (MACS system, Miltenyi Biotec, Sunnyvale, CA). Flow-through cells were collected, and the eluted basophil purities were between 98 and 99.4%.

Basophils are the only leukocytes in these preparations to release histamine and LTC4 in response to FMLP and anti-IgE (2). Studies also show that basophils are the major, if not the sole, source of IL-4 following IgE-dependent activation (3). As a result, basophil-enriched mixed leukocyte suspensions were used to evaluate the effect of PD98059 on histamine, LTC4, and IL-4 secretion. Venous blood from consenting donors was anticoagulated with 10 mM EDTA, and basophil-enriched suspensions were prepared by a double-Percoll density centrifugation, as previously described (37). The purity of the basophils in the cell suspensions ranged from 2–15%.

Western blot analysis of whole cell lysates

High speed cell pellets (~14,000 x g, 5–10 s) were resuspended at 2 x 107 cells/ml in lysis buffer (50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM EGTA, 5 mM DTT, 1% Nonidet P-40, 1 mM PMSF, 20 µg/ml leupeptin, 100 µg/ml aprotinin, and 10 mM benzamidine). After 20 s of vortexing, the cell lysates were kept on ice for 20 min and then microfuged for 15 min at 4°C. Supernatant was collected as a protein extract containing lysed cell components without nuclei. Extracts from an equal number of basophils (2 x 105 cell equivalents/lane) were diluted with an equal volume of 2x loading buffer (0.125 M Tris-HCl (pH 6.8), 4% SDS, 0.005% bromophenol blue, and 20% glycerol; NOVEX, San Diego, CA) containing 0.05% 2-ME and subjected to 10% Tris-glycine gradient gel electrophoresis (NOVEX). Gels were then transferred to pure nitrocellulose membranes (Schleicher & Schuell, Keene, NH) with a Trans Blot (NOVEX). Electrophoresis and transfers were performed according to the manufacturer’s recommendations. After transfer, membranes were immersed in TBST (50 mM Tris (pH 7.5), 0.15 M NaCl, and 0.05% Tween-20) containing 5% nonfat dried skim milk (Carnation, Los Angeles, CA) overnight to block nonspecific binding. Membranes were then washed three times (5 min each time) with TBST. Immunoreactive proteins were detected using anti-ERK-1 Ab, anti-ERK-2 Ab, or anti-p38 MAPK Ab, which were diluted (at 0.5 µg/ml) in TBST containing 1% skim milk. After a 4-h incubation, membranes were washed with TBST and then incubated with peroxidase-conjugated anti-rabbit Ig Ab for 1 h. After five 10-min washes, membrane-bound anti-rabbit Ig Ab was visualized with ECL Western blotting detection reagents (Amersham), and HyperECL luminescence detection film (Amersham). The enhanced chemiluminescence film images were converted to digital format with a URL digital camera, and the images were analyzed with National Institutes of Health Image (Wayne Rasband, National Institutes of Health, Bethesda, MD) (26, 36). Although the comparisons were made on the basis of equal numbers of cells, the protein contents of these samples were also found to be equal.

Phosphorylation of ERKs, p38 MAPK, and cPLA2

The phosphorylation of ERKs was assessed using three different techniques: 1) anti-phospho-ERK Ab (38), 2) anti-phosphotyrosine Ab (4G10) (39, 40), and 3) electrophoretic mobility shift, using anti-ERK-1 and anti-ERK-2 Abs (23, 39). The phosphorylation of p38 MAPK was assessed using anti-phospho-p38 MAPK Ab or anti-phosphotyrosine Ab (41, 42). The phosphorylation of cPLA2 was assessed using electrophoretic mobility shift with anti-cPLA2 Abs (16, 26). After stimulating basophils in PAGCM buffer, reactions were stopped by adding ice-cold PAG and were microfuged for 5–10 s. Cell pellets were immediately lysed in lysis buffer (20 mM Tris (pH 7.5), 2 mM EDTA, 2 mM EGTA, 5 mM DTT, 1 mM PMSF, 10 mM benzamidine, 100 µg/ml aprotinin, 200 µg/ml leupeptin, 50 mM NaF, 5 mM Na4P2O7, 1 mM Na3VO4, and 1% Nonidet P-40). Extracts containing equal basophil cell numbers (5 x 105 cell equivalents/lane) were diluted with an equal volume of 2x loading buffer and subjected to 10% Tris glycine gel (NOVEX). After electrophoresis (160 V and 1.5 h for detection of MAPKs phosphorylation, and 160 V and 3.5 h for cPLA2 phosphorylation), proteins were transferred to nitrocellulose membranes (as described above). The membranes were immersed overnight in TBST containing 2% BSA (for detection by 4G10) or in TBST containing 5% nonfat dry skim-milk (Carnation) for the others. Immunoreactive proteins were detected using 4G10 in TBST containing 1% BSA or anti-ERK-1 Ab, anti-ERK-2 Ab, anti-cPLA2 Ab, anti-phospho-ERK Ab, or anti-phospho-p38 MAPK Ab, which were diluted in TBST containing 1% skim milk for 4 h. After washing, the membranes were incubated for 1 h with horseradish peroxidase-conjugated anti-mouse Ab (for 4G10) or horseradish peroxidase-conjugated anti-rabbit Ab (for the other Abs). After washing, enhanced chemiluminescence detection was performed as described above. For kinetic studies, the same membranes were detected by anti-phospho-ERK Ab, anti-ERK-1 Ab, and anti-ERK-2 Ab or anti-phospho-p38 MAPK Ab and anti-p38 MAPK Ab. Between each detection, membranes were stripped with stripping buffer (62.5 mM Tris-HCl (pH 6.7), 100 mM 2-ME, and 2% SDS) for 1 h at 50°C. In preliminary experiments the techniques to assess phosphorylation of ERKs were simultaneously compared using phosphorylated and nonphosphorylated ERK-2 (p42MAPK) proteins. Both phospho-ERK Ab and 4G10 recognized only phosphorylated ERK-2. Although the anti-ERK-2 Ab recognized both phosphorylated and nonphosphorylated ERK-2, the phosphorylated protein migrated more slowly than the nonphosphorylated protein, indicating that this Ab might also be useful in assessing phosphorylation of ERK-2 by recognizing both the phosphorylated and the nonphosphorylated form.

LTC4 and histamine measurements

Fifty thousand basophils were challenged in a final volume of 100 µl of PAGCM at 37°C. The reactions were terminated with 900 µl of ice-cold PAG-EDTA, and the cells were then centrifuged in a microfuge at 14,000 rpm for 10 s. A RIA was performed using 100 µl of supernatant to determine LTC4 levels as previously described (1, 43). An additional 500 µl of supernatants was mixed with an equal volume of PAG to measure histamine by automated fluorometry (44). The percentage of total histamine release was calculated for the diluted supernatants after subtraction of spontaneous histamine release (45). Each condition tested was performed in duplicate.

IL-4 measurements

Fifty thousand basophils were challenged in a final volume of 100 µl of RPMI 1640 with 0.03% HSA (37°C, 5% CO2 incubator). After 4 h, the supernatants were harvested by centrifugation of microtiter plates (150 x g, 3 min). The supernatants were stored at -80°C until analysis. IL-4 measurements were performed using an in-house ELISA, as previously described (46). Each condition tested was performed in duplicate.

AA measurements

The mass of AA was determined via combined capillary gas chromatography-negative ion chemical ionization mass spectrometry using modifications of previously described procedures (47, 48). One hundred thousand cells were challenged in a final volume of 100 µl of PAGCM at 37°C. The reactions were terminated by the addition of 1 ml of acetone followed immediately by the addition of 15–20 ng of octodeuterated AA (as an internal standard). Reaction mixtures were transferred to glass vials and dried under dry N2. The carboxyl moieties of AA were converted to pentafluorobenzyl esters as previously described (47). Once derivatized, the residue was dissolved in 60 µl of dodecane for injection into the gas chromatograph. The measurement of released AA by gas chromatography-negative ion chemical ionization mass spectrometry was performed as previously described (47, 48). Each condition tested was performed in duplicate.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Expression of ERKs (ERK-1/2) and p38 MAPK in human basophils

To determine whether ERK-1, ERK-2, and p38 MAPK were present in human basophils, basophils that were very close to 100% purity obtained by anti-IgE positive selection were prepared as described in Materials and Methods. This study included a comparative analysis with the contaminating cells (mainly monocytes and lymphocytes) that typically contaminate enriched basophil preparations. The collected cells that washed through the magnetized mini-MACS column yielded contaminating cells that contained <=1% basophils. The subsequently collected basophils ranged in purity between 98–99.4%. The cell lysates from the two populations were examined by Western blotting (Fig. 1Go). Nonphosphorylated ERK-2 (p42MAPK) protein was used as a positive control. The anti-ERK-2 Ab recognized only ERK-2, while the anti-ERK-1 Ab recognized ERK-1 and, to a lesser extent, ERK-2. The results indicated that basophils and contaminating cells expressed essentially equivalent levels of ERK-1/2 and p38 MAPK. The intensities of bands were assessed by image analysis from three different experiments. Human basophils expressed ERK-1 (130 ± 20% of contaminating cells), ERK-2 (97 ± 6% of contaminating cells; n = 3), and p38 MAPK (166 ± 12% of contaminating cells; n = 2). Our previous studies indicate that cPLA2 is also expressed at equivalent levels in basophils and contaminating cells (26). Thus, for all the experiments examining the phosphorylation of ERKs, p38 MAPK, and cPLA2 by Western blot, cell suspensions of >80% basophils were used to minimize the contribution from contaminating cells.



View larger version (50K):
[in this window]
[in a new window]
 
FIGURE 1. Expression of ERK-1/2 and p38 MAPK in human basophils and contaminating cells. Basophils (purity, 98–99.4%) and contaminating cells (basophil purity, <1%), which typically contaminate enriched basophil preparations (mainly lymphocytes and monocytes), were lysed at 2 x 107 cells/ml. The lysates containing 2 x 105 cells or recombinant-ERK-2 (p42MAPK) control protein (10 ng) were subjected to Western blot analysis as described in Materials and Methods. The Western blot shown is representative of three separate experiments.

 
Kinetics of phosphorylation of ERKs and cPLA2 and mediator release following stimulation with FMLP

As noted above, basophils activated with FMLP release histamine and generate free AA/LTC4, much like they do following IgE-dependent activation. We have shown more recently that FMLP also induces the phosphorylation of cPLA2 at a time consistent with free AA/LTC4 generation (26). We therefore examined the relationship between histamine release and free AA/LTC4 generation with the time course of FMLP-induced phosphorylation of ERKs. As shown in Fig. 2GoA, the phosphorylation of ERK-1 and -2 did occur, as assessed by the three different Abs described in Materials and Methods. In these experiments, phosphorylated and nonphosphorylated ERK-2 proteins were used as a reference. Thus, an electrophoretic mobility shift of ERK-1 and -2 was detected by anti-ERK-1 and anti-ERK-2 Abs, respectively. An identical time course in the phosphorylation of ERK-1 and -2 was detected by anti-phospho-ERK Ab (Fig. 2GoA) and by anti-phosphotyrosine Ab (4G10; data not shown). The phosphorylation of ERK-1 and -2 following FMLP stimulation was modest at 30 s, but a more significant level of phosphorylation was observed after 1 min, with maximal phosphorylation seen after 5 min (Fig. 2Go, A and B). By 15 min, phosphorylation had decreased toward basal levels. The phosphorylation of cPLA2, the generation of free AA, and LTC4 release coincided with or followed the phosphorylation of ERK-1/2. Unlike ERK-1/2, cPLA2 remained phosphorylated at 15 min. On the other hand, histamine release was nearly complete (80 ± 1% of maximum histamine release) within 30 s. These results are consistent with our previous findings that there is no lag time for histamine release, whereas there is a lag time (~1 min) before the generation of free AA/LTC4 following FMLP activation (47).



View larger version (25K):
[in this window]
[in a new window]
 
FIGURE 2. Kinetics of phosphorylation of ERKs and cPLA2, histamine release, and free AA/LTC4 generation induced by FMLP. Basophils were stimulated with FMLP (1 µM) for the times indicated. Reactions were stopped with the addition of ice-cold PAG, and the cells were microfuged. Supernatants were collected for histamine and LTC4 measurements. Cell pellets were lysed and subjected to Western blot analysis as described in Materials and Methods. Free AA analysis was also performed in parallel. A, The Western blot shown is representative of two separate experiments. B, The values are the mean ± range of two experiments. The percent histamine release, LTC4 release, and free AA generation at maximum time point were 91 ± 5%, 136 ± 11 pmol/106 basophils, and 29 ± 9 pmol/106 basophils, respectively. The intensities of the bands detected by anti-phospho-ERK are also plotted.

 
Kinetics of phosphorylation of ERKs and cPLA2, and mediator release in response to anti-IgE

In the next series of experiments, we examined the relationship between the phosphorylation of ERKs and the release of histamine and LTC4 in response to IgE-dependent stimulation. As shown in Fig. 3Go, A and B, there was no detectable phosphorylation of ERK-1/2 following anti-IgE activation for 1 min. However, both ERKs were maximally phosphorylated by 5 min, with levels decreasing toward baseline by 30 min. Unlike activation with FMLP, histamine release followed the phosphorylation of ERKs. The cPLA2 phosphorylation and LTC4 release also followed or coincided with ERK-1/2 phosphorylation. Anti-IgE-mediated phosphorylation of ERKs was also transient compared with phosphorylation of cPLA2.



View larger version (23K):
[in this window]
[in a new window]
 
FIGURE 3. Kinetics of ERKs and cPLA2 phosphorylation, histamine release, and LTC4 generation following stimulation with anti-IgE Ab. Basophils were stimulated with anti-IgE (100 ng/ml) for the times indicated. Reactions were stopped with the addition of ice-cold PAG, and the cells were microfuged. Supernatants were collected for histamine and LTC4 assays. Cell pellets were lysed and subjected to Western blot as described in Materials and Methods. A, The Western blot is representative of two separate experiments. B, The values are the mean ± range of two experiments. The percent histamine release and LTC4 release at 30 min were 62 ± 18% and 61 ± 24 pmol/106 basophils. The intensities of the bands detected by anti-phospho-ERK are also plotted.

 
Basophil histamine release varies considerably among donor cells undergoing IgE-mediated stimulation (49, 50). Basophils from some donors are essentially unresponsive to IgE-mediated stimulation, the so-called nonreleasing basophils (49, 50). Not included in the data shown in Fig. 3Go were the results for a nonreleasing donor. Anti-IgE-mediated phosphorylation of ERKs and cPLA2 was not detected; there was also no LTC4 release (data not shown). Taken together, anti-IgE-mediated ERK activation may be associated with the pathway leading to histamine release and LTC4 generation.

Kinetics of phosphorylation of p38 MAPK following stimulation with FMLP or anti-IgE Ab

The kinetics of phosphorylation of p38 MAPK following stimulation with FMLP or anti-IgE Ab were also examined. As shown in Fig. 4GoA, a significant phosphorylation of p38 MAPK was observed following stimulation with FMLP. The kinetics were slightly faster (a significant phosphorylation was observed at 30 s, with a maximum from 1–5 min and a decrease toward the basal level by 15 min) than those of phosphorylation of ERKs. Similar results were obtained with anti-phosphotyrosine Ab (4G10) blot (data not shown). Anti-IgE Ab also induced modest phosphorylation of p38 MAPK at 1 min, and maximum phosphorylation was seen from 5–15 min (Fig. 4GoB). By 30 min, the phosphorylation decreased toward basal levels. Similar results were obtained with anti-phosphotyrosine Ab blot (data not shown). Taken together with previous results, p38 MAPK may contribute to mediator release in human basophils.



View larger version (35K):
[in this window]
[in a new window]
 
FIGURE 4. Kinetics of phosphorylation of p38 MAPK following stimulation with FMLP or anti-IgE Ab. Basophils were stimulated with FMLP (1 µM; A) or anti-IgE (100 ng/ml; B) for the times indicated. Reactions were stopped by the addition of ice-cold PAG. Cell pellets were lysed and subjected to Western blot as described in Materials and Methods. The anti-p38 MAPK Ab blot indicates equal protein loading. The Western blot is representative of two separate experiments.

 
Effect of PD98059 on tyrosine phosphorylation induced by FMLP

As noted, MEKs (MAP kinase kinases) are dual specificity kinases that phosphorylate substrates (ERKs) on both Tyr and Thr residues and increase the catalytic activity of ERKs (51, 52). PD98059 is a well-known inhibitor of MEK (MAPK kinase). This compound blocks the activation (and phosphorylation) of MEK through an allosteric mechanism that does not involve inhibition of ATP binding (53). The potency and specificity of this inhibitor have been extensively documented in a variety of biologic systems (24, 53, 54, 55). It has been shown that IgE-mediated phosphorylation of ERK-2 and cPLA2 are specifically inhibited by PD98059 in RBL-2H3 cells (24).

As shown in Fig. 5GoA, this also appears to be true in human basophils. The phosphorylation of ERKs induced by FMLP was prevented by PD98059, whereas the phosphorylation of tyrosine in other proteins, including 38 (p38 MAPK)-, 62-, 100-, and 115-kDa proteins was not significantly affected by this compound. Similar to phosphorylated 38-kDa protein (p38 MAPK) in anti-phosphotyrosine Ab blot, phospho-p38 MAPK Ab blot also confirmed that PD98059 did not affect phosphorylation of p38 MAPK (Fig. 5GoB). The electrophoretic mobility shift of cPLA2 was also inhibited (Fig. 5GoA), suggesting that PD98059 specifically blocks the ERK-cPLA2 pathway but not the pathway for p38 MAPK in human basophils.



View larger version (36K):
[in this window]
[in a new window]
 
FIGURE 5. A, The effect of PD98059 on phosphorylation of ERKs and cPLA2 stimulated by FMLP. B, The effect of PD98059 on phosphorylation of p38 MAPK stimulated by FMLP. Basophils were preincubated with PD98059 (100 µM) or DMSO (1/1000 dilution) for 1 h and were stimulated with FMLP (1 µM) for 1 min. Reactions were stopped by the addition of ice-cold PAG, and the cells were centrifuged. The cell pellets were lysed, and the lysates were subjected to Western blot analysis as described in Materials and Methods. The anti-p38 MAPK Ab blot indicates equal protein loading. The Western blot shown is representative of two separate experiments. Open, closed, and hatched arrows indicate phosphorylated ERK-2, ERK-1, and p38 MAPK, respectively.

 
Effect of PD98059 on histamine release and LTC4 release following stimulation with FMLP

To evaluate the involvement of the MEK-ERK pathway in LTC4 generation and histamine release, the effect of PD98059 on the secretion of these mediators was tested. For these experiments, basophil-enriched suspensions freshly prepared from blood or cell suspensions derived from leukocyte packs were used (purity ranged from 2–75%). PD98059 did not affect FMLP-induced histamine release (Fig. 6GoA). In contrast, PD98059 inhibited FMLP-induced LTC4 release (76 ± 5% inhibition at 100 µM and 64 ± 16% inhibition at 10 µM), whereas the same dilution of DMSO did not affect the release of LTC4 (Fig. 6GoB). The IC50 for the inhibition of LTC4 by PD98059 was approximately 2 µM, comparable to values (2–4 µM) reported for the inhibition of MEK and ERK in other cell types (53, 54, 55). The effect of PD98059 on FMLP-induced generation of free AA was also examined. In this series of experiments, the cells were stimulated with FMLP for 5 min, since this amount of time results in maximal free AA generation (Fig. 2GoB). FMLP-induced free AA generation was also inhibited by PD98059 (57 ± 8% inhibition at 100 µM and 41 ± 7% at 10 µM compared with DMSO control; n = 3). Taken together, these results suggest that FMLP activation uses the MEK-ERK pathway for free AA/LTC4 generation but not histamine release.



View larger version (13K):
[in this window]
[in a new window]
 
FIGURE 6. The effects of PD98059 on histamine release (A) and LTC4 generation (B) following stimulation with FMLP. Basophils were pretreated with 0–100 µM PD98059 (closed symbols) or the same dilutions of DMSO (open symbols) for 1 h and then incubated in the presence or the absence of FMLP (1 µM) for 30 min. Reactions were terminated by addition of ice-cold PAG-EDTA. The values are the mean ± SEM of three experiments. The control percent histamine release and LTC4 generation (without PD98059 and DMSO) were 48 ± 9% and 53 ± 15 pmol/106 basophils, respectively.

 
Effect of PD98059 on histamine release, LTC4 generation, and IL-4 production following stimulation with anti-IgE

The kinetic studies, shown in Fig. 3Go, suggested that the anti-IgE-mediated activation of ERKs may be associated with histamine release as well as LTC4 release. Further, ERKs also regulate several transcriptional factors (14) that may potentially have a role in cytokine production from human basophils. The effects of PD98059 on anti-IgE-mediated secretion of histamine, LTC4, and IL-4 were examined (Fig. 7Go). Based on previous experiments to determine the optimal concentrations of anti-IgE to induce histamine and LTC4 release (3), or IL-4 production, 100 ng/ml (for histamine and LTC4 release) and 10 ng/ml (for IL-4 production) of anti-IgE were used. As observed for FMLP activation, anti-IgE-induced LTC4 was inhibited by PD98059 (85 ± 10% inhibition at 100 µM and 80 ± 14% inhibition at 10 µM), with an IC50 of approximately 2 µM. In contrast, histamine release (11 ± 10% inhibition at 100 µM) and IL-4 production (37 ± 7% inhibition at 100 µM vs 14 ± 12% inhibition with DMSO control) were only marginally inhibited by PD98059, suggesting that ERKs are not important in histamine release or IL-4 production.



View larger version (12K):
[in this window]
[in a new window]
 
FIGURE 7. The effects of PD98059 on histamine release (A), LTC4 generation (B), and IL-4 production (C) following stimulation with anti-IgE Ab. Basophils were pretreated with 0–100 µM PD98059 (closed symbols) or with the same dilutions of DMSO (open symbols) for 1 h and then incubated in the presence or the absence of anti-IgE (100 ng/ml for histamine and LTC4 or 10 ng/ml for IL-4) for 30 min (histamine and LTC4) or 4 h (IL-4). Reactions were terminated by addition of ice-cold PAG-EDTA. The values are the mean ± SEM of three experiments. The control percent histamine release, LTC4 generation, and IL-4 (without PD98059 and DMSO) were 53 ± 15%, 79 ± 66 pmol/106 basophils, and 330 ± 129 pg/106 basophils, respectively.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ERKs have been shown to phosphorylate and activate cPLA2, resulting in its increased enzymatic activity (16). This phosphorylation of cPLA2 along with its translocation to the membrane (mediated by the increase in cytosolic calcium) are required for its full activity (56, 57). Indeed, our previous studies showed that the accumulation of free AA and the generation of LTC4 followed an increase in cytosolic calcium and the phosphorylation of cPLA2, suggesting that the activation of cPLA2 provides free AA for LTC4 generation in human basophils (26). At that time, we were unable to link cPLA2 involvement, since a selective inhibitor of cPLA2 was not available. In the present study we have provided further evidence to support the concept that cPLA2 has a role in LTC4 generation by implicating a MEK-ERK pathway. These data also suggest that ERKs regulate cPLA2 activation for LTC4 generation in human basophils. First, the phosphorylation of ERK-1/2 preceded or coincided with the phosphorylation of cPLA2 and the release of LTC4 in both FMLP- and anti-IgE-mediated stimulation, demonstrating a kinetic association among ERK phosphorylation, cPLA2 phosphorylation, and LTC4 release. We did not detect a preference for ERK-1 and ERK-2 phosphorylation following stimulation with either FMLP or anti-IgE. It should be noted that cPLA2 remained phosphorylated within the time frame examined (15 min for FMLP and 30 min for anti-IgE), although phosphorylation of ERKs decreased toward the basal level following stimulation with anti-IgE or FMLP. Similar results have been reported for cPLA2 phosphorylation in other cell types. In endothelial cells, fibroblast growth factor-mediated phosphorylation of p42MAPK (ERK-2) is also more transient than phosphorylation of cPLA2 (58). ERKs and cPLA2 might be differentially dephosphorylated by different phosphatases after phosphorylation (58). Second, a selective inhibitor of the MEK-ERK pathway, PD98059, inhibited LTC4 release induced by FMLP and anti-IgE. The phosphorylations of ERK-1/2 and cPLA2 and the generation of free AA induced by FMLP were also inhibited by PD98059, without affecting other tyrosine-phosphorylated proteins (including p38 MAPK). Collectively, these results suggest a causal relationship between ERK activation and LTC4 generation (presumably by the activation of cPLA2) in human basophils. These results also indicate that regulation of cPLA2 for generating AA in human basophils is distinct from that in platelets (30). In collagen-stimulated platelets, p38 MAPK, but not ERKs, might regulate activation (phosphorylation) of cPLA2. PD98059 also fails to inhibit phosphorylation of cPLA2 induced by collagen (30). The activation of cPLA2 by p38 MAPK may be restricted to certain cell types or stimuli. In other cell types, ERKs are thought to regulate activation of cPLA2 (16, 58, 59), which are also supported by the results using PD98059 (24, 60).

FMLP-induced histamine release preceded the phosphorylation of ERKs and was unaffected by inhibition of the MEK-ERK pathway by PD98059. These results strongly suggest that the activation of ERKs is not involved in FMLP-mediated degranulation. In contrast, the release of histamine and LTC4 induced by anti-IgE was consistent with the time course of phosphorylation of ERKs. The kinetics of histamine release induced by anti-IgE are slower than those of FMLP (1, 47). Previous data suggested that the sustained elevation in cytosolic calcium that follows IgE-mediated stimulation was associated with histamine release. However, histamine release only follows elevations in cytosolic calcium after an interval of 2–3 min, suggesting the need for signaling events that are slower to evolve. This rate-limiting event for histamine release remains unclear, but the slower activation of ERK-1/2 suggested one possibility. However, the inhibition of the MEK-ERK pathway by PD98059 only marginally affected histamine release, suggesting little causal relationship between histamine release and ERK activation. Taken together with the results for FMLP, ERKs appears to have little role in any receptor-mediated degranulation in human basophils. It is useful to note that similar observations have been made in RBL-2H3 cells. PD98059 inhibited the release of AA; however, degranulation (hexosaminidase release) was only slightly affected in RBL-2H3 cells (24).

The activation of ERKs also induces c-Fos expression (which constitutes part of the AP-1 complex) (15), the inactivation of I{kappa}B (61), and enhanced binding activity of cytokine transcriptional factors such as NF-{kappa}B and activating protein-1 (62). In RBL-2H3 cells, IgE-mediated TNF-{alpha} production is inhibited by PD98059, suggesting that the MEK-ERK pathway is involved in the IgE-dependent production of this cytokine (24). In contrast, the same compound does not affect the similar IgE-dependent production of TNF-{alpha} in distinct cells (MC/9 murine mast cells), suggesting that the MEK-ERK pathway does not regulate this cytokine. However, the other MAPKs, JNKs, have been shown to mediate this cytokine (25). These conflicting data suggest that roles of ERKs for production of cytokines appear to be dependent on cell type or species. Therefore, it is important to determine the role of ERKs in normal human cells. Human basophils produce IL-4, and there is no evidence of TNF-{alpha} production from human basophils. We observed only minor inhibition of IL-4 production by PD98059 at 100 µM in human basophils. Furthermore, the transient activation of ERK-1/2 is not consistent with the time scale of IL-4 secretion. Since disaggregating cell surface cross-links at times greater than 30 min stops IL-4 secretion, there appears to be a need for sustained signaling, and the transient nature of ERK-1/2 phosphorylation is not consistent with this requirement. Taken together, the activation of ERKs may not be involved in IgE-mediated IL-4 production from human basophils. This belief is further supported by the evidence that FMLP, which induces the phosphorylation of ERKs, is a poor stimulus of IL-4 production from human basophils (3). At this time, there is more evidence to suggest that a transcription factor resembling the nuclear factor of activated T cells (NF-AT) has a greater role in IL-4 generation by these cells (63). It remains possible that the activation of ERKs may contribute to the synthesis of other proteins.

We also demonstrated the expression and phosphorylation of p38 MAPK in human basophils. Kinetics studies revealed that phosphorylation of p38 MAPK is slightly faster than that of ERKs following stimulation of either anti-IgE or FMLP, suggesting that p38 MAPK may regulate or modulate mediator release in human basophils. The inhibition of ERK pathway by PD98059 abrogated AA/LTC4 generation without affecting phosphorylation of p38 MAPK. These results may suggest that ERKs rather than p38 MAPK are essential for the pathway generating AA/LTC4. The precise role of p38 MAPK in mediator release remains to be elucidated. We are currently investigating this issue.

In summary, the activation of ERKs appears to be a key step necessary for the phosphorylation and activation of cPLA2, which is important for liberating free AA for LTC4 generation in human basophils. However, ERKs have no apparent role in supporting histamine and IL-4 release.


    Footnotes
 
1 This work was supported by National Institutes of Health Grant AI20253. Back

2 Address correspondence and reprint requests to Dr. Donald W. MacGlashan, Jr., Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224. E-mail address: Back

3 Abbreviations used in this paper: LTC4, leukotriene C4; AA, arachidonic acid; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; MEK, MAPK kinase; MEKK, MAPK kinase kinase; cPLA2, cytosolic phospholipase A2; HSA, human serum albumin; PAG, PIPES-albumin-glucose. Back

Received for publication July 13, 1998. Accepted for publication December 30, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Jr MacGlashan, D. W., S. P. Peters, J. Warner, L. M. Lichtenstein. 1986. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J. Immunol. 136:2231.[Abstract]
  2. Warner, J. A., S. P. Peters, L. M. Lichtenstein, W. Hubbard, K. B. Yancey, H. C. Stevenson, P. J. Miller, Jr D. W. MacGlashan. 1989. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J. Leukocyte Biol. 45:558.[Abstract]
  3. Jr MacGlashan, D. W., J. M. White, S. K. Huang, S. J. Ono, J. Schroeder, L. M. Lichtenstein. 1994. Secretion of interleukin-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J. Immunol. 152:3006.[Abstract]
  4. Brunner, T., C. H. Heusser, C. A. Dahinden. 1993. Human peripheral blood basophils primed by interleukin-3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J. Exp. Med. 177:605.[Abstract/Free Full Text]
  5. Charlesworth, E. N., A. F. Hood, N. A. Soter, S. A. Kagey, P. S. Norman, L. M. Lichtenstein. 1989. Cutaneous late-phase response to allergen: mediator release and inflammatory cell infiltration. J. Clin. Invest. 83:1519.
  6. Bascom, R., M. Wachs, R. M. Naclerio, U. Pipkorn, S. J. Galli, L. M. Lichtenstein. 1988. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J. Allergy Clin. Immunol. 81:580.[Medline]
  7. Guo, C. B., M. C. Liu, S. J. Galli, B. S. Bochner, A. Kagey-Sobotka, L. M. Lichtenstein. 1993. Identification of IgE bearing cells in the late response to antigen in the lung as basophils. Am. J. Respir. Cell Mol. Biol. 10:384.[Abstract]
  8. Serhan, C. N., J. Z. Haeggstrom, C. C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147.[Abstract]
  9. Steinhiblber, D.. 1994. 5-Lipoxygenase: expression and regulation of activity. Pharm. Acta Helv. 69:3.[Medline]
  10. Kurimoto, Y., A. L. de Weck, C. A. Dahinden. 1989. Interleukin 3-dependent mediator release in basophils triggered by C5a. J. Exp. Med. 170:467.[Abstract/Free Full Text]
  11. Blenis, J.. 1993. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. USA 90:5889.[Abstract/Free Full Text]
  12. Seger, R., E. G. Krebs. 1995. The MAPK signaling cascade. FASEB J. 9:726.[Abstract]
  13. Payne, D. M., A. J. Roissamando, P. Martino, J.-H. Erickon, J. Shabanowitz, D. F. Hunt, M. J. Weber, T. W. Sturgill. 1991. Identification of regulatory phosphorylation sites in p42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10:855.
  14. Hill, S. H., R. Treisman. 1995. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80:199.[Medline]
  15. Gille, H., D. Sharrocks, P. E. Shaw. 1992. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-Fos promoter. Nature 358:414.[Medline]
  16. Lin, L.-L., M. Wartmann, A. Lin, J. L. Knoph, A. Seth, R. J. Davis. 1993. cPLA2 is phosphorylated and activated by MAP kinase. Cell 72:269.[Medline]
  17. Eiseman, E., J. B. Bolen. 1992. Engagement of the high-affinity IgE receptor activates Src protein-related tyrosine kinases. Nature 355:78.[Medline]
  18. Hutchcroft, J. E., R. L. Geahlen, G. G. Deanin, J. M. Oliver. 1992. Fc{epsilon}RI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells. Proc. Natl. Acad. Sci. USA 89:9107.[Abstract/Free Full Text]
  19. Jouvin, M. H., M. Adamczewski, R. Numerof, O. Letourneur, A. Valle, J. P. Kinet. 1994. Differential control of the tyrosine kinase Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J. Biol. Chem. 269:5918.[Abstract/Free Full Text]
  20. Benhamou, M., J. S. Gutkind, K. C. Robbins, R. P. Siraganian. 1990. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. Proc. Natl. Acad. Sci. USA 87:5327.[Abstract/Free Full Text]
  21. Benhamou, M., R. P. Shiraganian. 1992. Protein-tyrosine phosphorylation: an essential component of Fc{epsilon}RI signaling. Immunol. Today 13:195.[Medline]
  22. Hirasawa, N., F. Santini, M. A. Beaven. 1995. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. J. Immunol. 154:5391.[Abstract]
  23. Offermanns, S., S. V. P. Jones, E. Bombien, G. Schultz. 1994. Stimulation of mitogen-activated protein kinase activity by different secretory stimuli in rat basophilic leukemia cells. J. Immunol. 152:250.[Abstract]
  24. Zhang, C., R. U. Baumgartner, K. Yamada, M. A. Beaven. 1997. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-{alpha} and release of arachidonic acid in mast cells: identification of communication between p38 and p42 MAP kinases. J. Biol. Chem. 270:27395.[Abstract/Free Full Text]
  25. Ishizuka, T., N. Terada, P. Gerwins, E. Hamelmann, A. Oshiba, G. R. Fanger, G. L. Johnson, E. W. Gelfand. 1997. Mast cell tumor necrosis factor {alpha} production is regulated by MEK kinases. Proc. Natl. Acad. Sci. USA 94:6358.[Abstract/Free Full Text]
  26. Miura, K., W. C. Hubbard, Jr D. W. MacGlashan. 1998. Phosphorylation of cytosolic phospholipase A2 by IL-3 is associated with increased free arachidonic acid generation and leukotriene C4 release in human basophils. J. Allergy Clin. Immunol. 102:512.[Medline]
  27. Hundley, T. R., L. Marshall, W. C. Hubbard, Jr D. W. MacGlashan. 1998. Characteristics of arachidonic acid generation in human basophils: relationship between the effects of inhibitors of secretory phospholipase A2 activity and leukotriene C4 release. J. Pharmacol. Exp. Ther. 284:847.[Abstract/Free Full Text]
  28. Kramer, R. M., E. F. Roberts, S. L. Um, A. G. Borsch-Haubold, S. P. Watson, M. J. Fisher, J. A. Jakubowski. 1996. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets: evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J. Biol. Chem. 271:27723.[Abstract/Free Full Text]
  29. Kramer, R. M., E. F. Roberts, B. A. Strifler, E. M. Johnstone. 1995. Thrombin induces activation of p38 MAP kinase in human platelets. J. Biol. Chem. 270:27395.
  30. Borsch-Haubold, A. G., R. M. Kramer, S. P. Watson. 1997. Phosphorylation and activation of cytosolic phospholipase A2 by 38-kDa mitogen-activated protein kinase in collagen-stimulated human platelets. Eur. J. Biochem. 245:751.[Medline]
  31. Kramer, R. M., E. F. Roberts, P. A. Hyslop, B. G. Utterback, K. Y. Hui, J. A. Jakubowski. 1995. Differential activation of cytosolic phospholipase A2 (cPLA2) by thrombin and thrombin receptor agonist peptide in human platelets: evidence for activation of cPLA2 independent of mitogen-activated protein kinases ERK1/2. J. Biol. Chem. 270:14816.[Abstract/Free Full Text]
  32. Ridley, S. H., S. J. Sarsfield, J. C. Lee, H. F. Bigg, T. E. Cawston, D. J. Taylor, D. L. DeWitt, J. Saklatvala. 1997. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J. Immunol. 158:3165.[Abstract]
  33. Hobbie, S., L. M. Chen, R. J. Davis, J. E. Galan. 1997. Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells. J. Immunol. 159:5550.[Abstract]
  34. Foey, A. D., S. L. Parry, L. M. Williams, M. Feldmann, B. M. Foxwell, F. M. Brennan. 1998. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-{alpha}: role of the p38 and p42/44 mitogen-activated protein kinases. J. Immunol. 160:920.[Abstract/Free Full Text]
  35. Gilbert, H. S., L. Ornstein. 1975. Basophil counting with a new staining method using Alcian blue. Blood 46:279.[Abstract/Free Full Text]
  36. Miura, K., Jr D. W. MacGlashan. 1998. Expression of protein kinase C isozymes in human basophils: regulation by physiological and nonphysiological stimuli. Blood 92:1206.[Abstract/Free Full Text]
  37. Schroeder, J. T., L. M. Lichtenstein, S. M. MacDonald. 1996. An immunoglobulin E-dependent recombinant histamine releasing factor induces interleukin-4 secretion from human basophils. J. Exp. Med. 183:1265.[Abstract/Free Full Text]
  38. Dumont, F. J., M. J. Staruch, P. Fischer, C. DaSilva, R. Camacho. 1998. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J. Immunol. 160:2579.[Abstract/Free Full Text]
  39. Zhang, C., N. Hirasawa, M. A. Beaven. 1997. Antigen activation of mitogen-activated protein kinase in mast cells through protein kinase C-dependent and independent pathways. J. Immunol. 1997:4968.
  40. Rose, D. M., B. W. Winston, E. D. Chan, D. W. H. Riches, P. Gerwins, G. L. Johnson, P. M. Henson. 1997. Fc{gamma} receptor cross-linking activates p42, p38, and JNK/SAPK mitogen-activated protein kinases in murine macrophages: role of p42 MAPK in Fc{gamma} receptor-stimulated TNF-{alpha} synthesis. J. Immunol. 158:3433.[Abstract]
  41. Maulon, L., S. Guerin, J. E. Ricci, D. F. Breittmayer, P. Auberger. 1998. T-cell receptor signaling pathway exerts a negative control on thrombin-mediated increase in [Ca2+]i and p38 MAPK activation in Jurkat T cells: implication of the tyrosine kinase p56Lck. Blood 91:4232.[Abstract/Free Full Text]
  42. Kumar, A., A. Middleton, T. C. Chambers, K. D. Mehta. 1998. Differential roles of extracellular signal-regulated kinase-1/2 and p38(MAPK) in interleukin-1ß- and tumor necrosis factor-{alpha}-induced low density lipoprotein receptor expression in HepG2 cells. J. Biol. Chem. 273:15742.[Abstract/Free Full Text]
  43. Hayes, E. C., D. L. Lombardo, Y. Girard. 1983. Measuring leukotrienes of slow-reacting substance of analphylaxis: development of a specific radioimmunoassay. J. Immunol. 131:429.[Abstract]
  44. Siraganian, R. P.. 1974. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal. Biochem. 57:383.[Medline]
  45. Schroeder, J. T., Jr D. W. MacGlashan, A. Kagey-Sobotka, J. M. White, L. M. Lichtenstein. 1994. IgE-dependent IL-4 secretion by human basophils: the relationship between cytokine production and histamine release in mixed leukocyte cultures. J. Immunol. 153:1808.[Abstract]
  46. Schroeder, J. T., L. M. Lichtenstein, S. M. MacDonald. 1997. Recombinant histamine releasing factor enhances immunoglobulin E-dependent interleukin-4 and -13 secretion by human basophils. J. Immunol. 159:447.[Abstract]
  47. Jr MacGlashan, D. W., W. C. Hubbard. 1993. Interleukin-3 alters free arachidonic acid generation in C5a-stimulated human basophils. J. Immunol. 151:6358.[Abstract]
  48. Hubbard, W. C., C. L. Litteist, M. C. Liu, E. R. Bleecher, J. C. Eggleston, T. C. McKensie, M. R. Boyd. 1986. Profiling of prostaglandin biosynthesis in biopsy fragments of human lung carcinoma and normal human lung by capillary gas chromatography-negative ion chemical ionization mass spectrometry. Prostaglandins 32:889.[Medline]
  49. Jr MacGlashan, D. W.. 1994. Signal transduction: mechanisms in basophils. J. Allergy Clin. Immunol. 94:1146.[Medline]
  50. Yamaguchi, M., K. Hirai, K. Ohta, K. Suzuki, S. Kitani, T. Takaishi, K. Ito, C. Ra, Y. Morita. 1996. Culturing in the presence of IL-3 converts anti-IgE nonresponding basophils into responding basophils. J. Allergy Clin. Immunol. 97:1279.[Medline]
  51. Zheng, C.-F., K.-L. Guan. 1993. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J. Biol. Chem. 268:23933.[Abstract/Free Full Text]
  52. Crews, C. M., A. Alessandrini, R. Erikson. 1992. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478.[Abstract/Free Full Text]
  53. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, A. R. Saltiel. 1996. PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489.[Abstract/Free Full Text]
  54. Pang, L., T. Sawada, S. J. Decker, A. R. Saltiel. 1995. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270:13585.[Abstract/Free Full Text]
  55. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridge, A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686.[Abstract/Free Full Text]
  56. Wijkander, J., R. Dundler. 1992. Macrophage arachidonate-mobilizing phospholipase A2: role of Ca2+ for membrane binding but not for catalytic activity. Biochem. Biophys. Res. Commun. 184:118.[Medline]
  57. Nalefski, E. A., L. A. Sultzman, D. M. Martin, R. W. Kriz, P. S. Towler, J. L. Knopf, J. D. Clark. 1994. Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca-dependent lipid binding domain and a Ca-independent catalytic domain. J. Biol. Chem. 269:18239.[Abstract/Free Full Text]
  58. Sa, G., G. Murugesan, M. Jaye, Y. Ivashchenko, P. L. Fox. 1995. Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated kinase-dependent phosphorylation pathway in endothelial cells. J. Biol. Chem. 270:2360.[Abstract/Free Full Text]
  59. Nemenoff, R. A., S. Winitz, N.-X. Qian, V. V. Putten, G. L. Johnson, L. E. Heasley. 1993. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule protein 2 kinase and protein kinase C. J. Biol. Chem. 268:1960.[Abstract/Free Full Text]
  60. Xing, M., P. A. Insel. 1996. Protein kinase C-dependent activation of cytosolic phospholipase A2 and mitogen-activated protein kinase by {alpha}1-adrenergic receptors in Madin-Darby canine kidney cells. J. Clin. Invest. 97:1302.[Medline]
  61. Li, S., J. M. Sedivy. 1993. Raf-1 protein kinase activates the NF-{kappa}B transcription factor by dissociating the cytoplasmic NF-{kappa}B-I{kappa}B complex. Proc. Natl. Acad. Sci. USA 90:9247.[Abstract/Free Full Text]
  62. Park, J.-H., L. Levitt. 1993. Overexpression of mitogen-activated protein kinase (ERK1) enhances T-cell cytokine gene expression: role of AP1, NF-AT, and NF-{kappa}B. Blood 82:2470.[Abstract/Free Full Text]
  63. Redrup, A. C., B. P. Howard, D. W. J. MacGlashan, A. Kagey-Sobotka, L. M. Lichtenstein, J. T. Schhroeder. 1998. Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J. Immunol. 160:1957.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
BloodHome page
T. Pecaric-Petkovic, S. A. Didichenko, S. Kaempfer, N. Spiegl, and C. A. Dahinden
Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33
Blood, February 12, 2009; 113(7): 1526 - 1534.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. M. Vonakis, D. W. MacGlashan Jr, N. Vilarino, J. M. Langdon, R. S. Scott, and S. M. MacDonald
Distinct characteristics of signal transduction events by histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced priming and activation of human basophils
Blood, February 15, 2008; 111(4): 1789 - 1796.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Vilarino, K. Miura, and D. W. MacGlashan Jr
Acute IL-3 Priming Up-Regulates the Stimulus-Induced Raf-1-Mek-Erk Cascade Independently of IL-3-Induced Activation of Erk
J. Immunol., September 1, 2005; 175(5): 3006 - 3014.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Demasi, L. G. Cleland, R. J. Cook-Johnson, G. E. Caughey, and M. J. James
Effects of Hypoxia on Monocyte Inflammatory Mediator Production: DISSOCIATION BETWEEN CHANGES IN CYCLOOXYGENASE-2 EXPRESSION AND EICOSANOID SYNTHESIS
J. Biol. Chem., October 3, 2003; 278(40): 38607 - 38616.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. M. Munoz, Y. J. Kim, A. Y. Meliton, K. P. Kim, S.-K. Han, E. Boetticher, E. O'Leary, S. Myou, X. Zhu, J. V. Bonventre, et al.
Human Group V Phospholipase A2 Induces Group IVA Phospholipase A2-independent Cysteinyl Leukotriene Synthesis in Human Eosinophils
J. Biol. Chem., October 3, 2003; 278(40): 38813 - 38820.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
B. F. Gibbs, K. E. S. Plath, H. H. Wolff, and J. Grabbe
Regulation of mediator secretion in human basophils by p38 mitogen-activated protein kinase: phosphorylation is sensitive to the effects of phosphatidylinositol 3-kinase inhibitors and calcium mobilization
J. Leukoc. Biol., August 1, 2002; 72(2): 391 - 400.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ahamed and H. Ali
Distinct Roles of Receptor Phosphorylation, G Protein Usage, and Mitogen-activated Protein Kinase Activation on Platelet Activating Factor-induced Leukotriene C4 Generation and Chemokine Production
J. Biol. Chem., June 14, 2002; 277(25): 22685 - 22691.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Miura, S. Lavens-Phillips, and D. W. MacGlashan Jr.
Localizing a Control Region in the Pathway to Leukotriene C4 Secretion Following Stimulation of Human Basophils with Anti-IgE Antibody
J. Immunol., December 15, 2001; 167(12): 7027 - 7037.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Ahamed, B. Haribabu, and H. Ali
Cutting Edge: Differential Regulation of Chemoattractant Receptor-Induced Degranulation and Chemokine Production by Receptor Phosphorylation
J. Immunol., October 1, 2001; 167(7): 3559 - 3563.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Miura, S. S. Saini, G. Gauvreau, and D. W. MacGlashan Jr
Differences in Functional Consequences and Signal Transduction Induced by IL-3, IL-5, and Nerve Growth Factor in Human Basophils
J. Immunol., August 15, 2001; 167(4): 2282 - 2291.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. R. Hundley, A. R. Prasad, and M. A. Beaven
Elevated Levels of Cyclooxygenase-2 in Antigen-Stimulated Mast Cells Is Associated with Minimal Activation of p38 Mitogen-Activated Protein Kinase
J. Immunol., August 1, 2001; 167(3): 1629 - 1636.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Zhu, H. Sano, K. P. Kim, A. Sano, E. Boetticher, N. M. Munoz, W. Cho, and A. R. Leff
Role of Mitogen-Activated Protein Kinase-Mediated Cytosolic Phospholipase A2 Activation in Arachidonic Acid Metabolism in Human Eosinophils
J. Immunol., July 1, 2001; 167(1): 461 - 468.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Ali, J. Ahamed, C. Hernandez-Munain, J. L. Baron, M. S. Krangel, and D. D. Patel
Chemokine Production by G Protein-Coupled Receptor Activation in a Human Mast Cell Line: Roles of Extracellular Signal-Regulated Kinase and NFAT
J. Immunol., December 15, 2000; 165(12): 7215 - 7223.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. H. Falcone, H. Haas, and B. F. Gibbs
The human basophil: a new appreciation of its role in immune responses
Blood, December 15, 2000; 96(13): 4028 - 4038.
[Full Text] [PDF]


Home page
BloodHome page
K. Miura and D. W. MacGlashan Jr
Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils
Blood, September 15, 2000; 96(6): 2199 - 2205.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Miura and D. W. MacGlashan Jr.
Dual Phase Priming by IL-3 for Leukotriene C4 Generation in Human Basophils: Difference in Characteristics Between Acute and Late Priming Effects
J. Immunol., March 15, 2000; 164(6): 3026 - 3034.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-i. Lee, K. Miura, X. Liu, and J. L. Zweier
Biphasic Regulation of Leukocyte Superoxide Generation by Nitric Oxide and Peroxynitrite
J. Biol. Chem., December 8, 2000; 275(50): 38965 - 38972.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miura, K.
Right arrow Articles by MacGlashan, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miura, K.
Right arrow Articles by MacGlashan, D. W., Jr.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS